About us Contacts Drug interactions: 390 212
Drug search by name

Orkambi (Lumacaftor and Ivacaftor Tablets) and Procardia

Determining the interaction of Orkambi (Lumacaftor and Ivacaftor Tablets) and Procardia and the possibility of their joint administration.

Check result:
Orkambi (Lumacaftor and Ivacaftor Tablets) <> Procardia
Relevance: 23.07.2023 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Consumer information for this interaction is not currently available.GENERALLY AVOID: Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized by the isoenzyme. Undetectable plasma levels have been reported for some calcium blockers when given orally. MANAGEMENT: Concomitant use of calcium channel blockers with potent CYP450 3A4 inducers should generally be avoided. However, if concomitant use is necessary, dosage adjustments as well as close monitoring of pharmacologic effects, particularly blood pressure, should be considered whenever a potent CYP450 3A4 inducer is added to or withdrawn from therapy. References "Product Information. Rifadin (rifampin)." Hoechst Marion-Roussel Inc, Kansas City, MO. "Product Information. Mycobutin (rifabutin)." Pharmacia and Upjohn, Kalamazoo, MI. Tada Y, Tsuda Y, Otsuka T, et al "Case report: nifedipine-rifampicin interaction attenuates the effect on blood pressure in a patient with essential hypertension." Am J Med Sci 303 (1992): 25-7

Professional:

GENERALLY AVOID: Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized by the isoenzyme. Undetectable plasma levels have been reported for some calcium blockers when given orally.

MANAGEMENT: Concomitant use of calcium channel blockers with potent CYP450 3A4 inducers should generally be avoided. However, if concomitant use is necessary, dosage adjustments as well as close monitoring of pharmacologic effects, particularly blood pressure, should be considered whenever a potent CYP450 3A4 inducer is added to or withdrawn from therapy.

References
  • "Product Information. Rifadin (rifampin)." Hoechst Marion-Roussel Inc, Kansas City, MO.
  • "Product Information. Mycobutin (rifabutin)." Pharmacia and Upjohn, Kalamazoo, MI.
  • Tada Y, Tsuda Y, Otsuka T, et al "Case report: nifedipine-rifampicin interaction attenuates the effect on blood pressure in a patient with essential hypertension." Am J Med Sci 303 (1992): 25-7
Orkambi (Lumacaftor and Ivacaftor Tablets)

Generic Name: ivacaftor / lumacaftor

Brand name: Orkambi

Synonyms: Orkambi

Procardia

Generic Name: nifedipine

Brand name: Adalat CC, Procardia, Procardia XL, Afeditab CR, Nifediac CC, Nifedical XL, Adalat

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.